Chronic myeloid leukaemia News and Research

RSS
CRISPR uncovers which gene fusions are critical for growth of cancer cells

CRISPR uncovers which gene fusions are critical for growth of cancer cells

Potential combination therapy against rare disease of the bone marrow could improve treatment

Potential combination therapy against rare disease of the bone marrow could improve treatment

OGT increases NGS cancer panel content to provide more flexibility for customization

OGT increases NGS cancer panel content to provide more flexibility for customization

Study provides new insight into development of immune cells

Study provides new insight into development of immune cells

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Scientists launch new virtual platform to aid global search for treatment of leukemia

Scientists launch new virtual platform to aid global search for treatment of leukemia

Delays in availability of new treatments and incomprehensible price rises disadvantage cancer patients

Delays in availability of new treatments and incomprehensible price rises disadvantage cancer patients

Leukaemia patients could safely reduce side effects of drug by cutting dose in half, study shows

Leukaemia patients could safely reduce side effects of drug by cutting dose in half, study shows

Salvage alloSCT remains option for progressing CML patients

Salvage alloSCT remains option for progressing CML patients

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Long-term dasatinib findings support first-line use in CML

Long-term dasatinib findings support first-line use in CML

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

CML treatment-free remission criteria outlined

CML treatment-free remission criteria outlined

BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

Bosutinib shows 'low' vascular, cardiac event risk profile

Bosutinib shows 'low' vascular, cardiac event risk profile

Imatinib-related symptom burden linked to adherence in Indian CML patients

Imatinib-related symptom burden linked to adherence in Indian CML patients

Frontline nilotinib supported for newly diagnosed CP-CML

Frontline nilotinib supported for newly diagnosed CP-CML

Pre-TKI cytokine profiling predicts CP-CML outcome

Pre-TKI cytokine profiling predicts CP-CML outcome